Skandinaviska Enskilda Banken AB publ Sells 19,193 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Posted by on May 14th, 2023

Skandinaviska Enskilda Banken AB publ trimmed its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 62.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,581 shares of the biopharmaceutical company’s stock after selling 19,193 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Halozyme Therapeutics were worth $659,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. US Bancorp DE raised its holdings in shares of Halozyme Therapeutics by 2.1% in the third quarter. US Bancorp DE now owns 11,305 shares of the biopharmaceutical company’s stock worth $447,000 after buying an additional 236 shares during the period. Dupont Capital Management Corp raised its holdings in shares of Halozyme Therapeutics by 3.7% in the fourth quarter. Dupont Capital Management Corp now owns 10,644 shares of the biopharmaceutical company’s stock worth $606,000 after buying an additional 382 shares during the period. ProShare Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 1.2% in the third quarter. ProShare Advisors LLC now owns 36,252 shares of the biopharmaceutical company’s stock worth $1,434,000 after buying an additional 423 shares during the period. Cooper Financial Group raised its holdings in shares of Halozyme Therapeutics by 6.3% in the fourth quarter. Cooper Financial Group now owns 7,378 shares of the biopharmaceutical company’s stock worth $420,000 after buying an additional 436 shares during the period. Finally, Inspire Investing LLC raised its holdings in shares of Halozyme Therapeutics by 9.7% in the third quarter. Inspire Investing LLC now owns 5,201 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 460 shares during the period. 96.32% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 11,061 shares of the firm’s stock in a transaction on Thursday, February 16th. The stock was sold at an average price of $49.26, for a total value of $544,864.86. Following the completion of the sale, the chief executive officer now owns 633,666 shares of the company’s stock, valued at approximately $31,214,387.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $48.39, for a total transaction of $483,900.00. Following the completion of the sale, the senior vice president now owns 143,477 shares of the company’s stock, valued at approximately $6,942,852.03. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Helen Torley sold 11,061 shares of Halozyme Therapeutics stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $49.26, for a total value of $544,864.86. Following the sale, the chief executive officer now directly owns 633,666 shares of the company’s stock, valued at approximately $31,214,387.16. The disclosure for this sale can be found here. Insiders sold 73,586 shares of company stock valued at $3,367,746 in the last quarter. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Stock Down 0.0 %

Halozyme Therapeutics stock opened at $32.98 on Friday. The company has a debt-to-equity ratio of 8.79, a current ratio of 5.65 and a quick ratio of 4.88. The stock has a market capitalization of $4.47 billion, a price-to-earnings ratio of 22.74, a PEG ratio of 0.44 and a beta of 1.21. Halozyme Therapeutics, Inc. has a 1-year low of $29.85 and a 1-year high of $59.46. The business has a fifty day moving average price of $35.96 and a 200-day moving average price of $46.83.

Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last posted its quarterly earnings data on Tuesday, February 21st. The biopharmaceutical company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.01. The firm had revenue of $181.50 million during the quarter, compared to analysts’ expectations of $186.07 million. Halozyme Therapeutics had a return on equity of 141.30% and a net margin of 30.62%. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 2.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on HALO shares. SVB Securities downgraded Halozyme Therapeutics from an “outperform” rating to a “market perform” rating and set a $42.00 price target on the stock. in a report on Thursday, March 16th. Piper Sandler upgraded Halozyme Therapeutics from a “neutral” rating to an “overweight” rating and set a $46.00 price objective on the stock in a report on Wednesday. JPMorgan Chase & Co. reduced their price objective on Halozyme Therapeutics from $54.00 to $52.00 and set an “overweight” rating on the stock in a report on Thursday, February 23rd. SVB Leerink downgraded Halozyme Therapeutics from an “outperform” rating to a “market perform” rating and set a $42.00 price objective on the stock. in a report on Thursday, March 16th. Finally, StockNews.com assumed coverage on Halozyme Therapeutics in a report on Thursday, March 16th. They set a “hold” rating on the stock. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $55.30.

Halozyme Therapeutics Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Further Reading

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.